Today: 29 April 2026
Lynas Rare Earths share price dips as traders brace for Feb 26 results and briefing
24 February 2026
1 min read

Lynas Rare Earths share price dips as traders brace for Feb 26 results and briefing

Sydney, Feb 24, 2026, 17:51 AEDT — The market has closed.

  • Lynas Rare Earths (ASX:LYC) slipped 0.5% to finish at A$15.78, reversing gains from the previous session.
  • The ASX barely budged, with investors holding off moves ahead of inflation figures and keeping an eye on tariff news.
  • Lynas is up next, with half-year results and a management briefing scheduled for Thursday.

Lynas Rare Earths slipped 0.5% to A$15.78 on Tuesday, paring back some of Monday’s gains as the session wound down with volatile swings. The shares bounced between A$16.38 at the high and A$15.78 at the low, with roughly 6.3 million shares traded, according to data.

This is coming up fast, with Lynas set to release its half-year results for the six months to Dec. 31, 2025 on Thursday. Investors are focused on updates around production, costs, and pricing. CEO Amanda Lacaze will hold a briefing for analysts and shareholders at 11 a.m. Sydney time that day, according to the company.

Australian shares barely budged, with the S&P/ASX 200 settling at 9,022.30 points. Bank stocks slipped, wiping out gains from the miners as traders stayed on edge before Wednesday’s CPI — a key inflation check — and fresh tariff talk out of the U.S. “The broader theme is caution,” said Tim Waterer, chief market analyst at KCM Trade. Indo Premier

Lynas stayed quiet on Tuesday, with no new ASX market announcements. Investors instead leaned on broader macro signals and set their sights on the week’s lineup.

According to a filing posted Monday, Lynas has drawn a “becoming a substantial holder” notice — a disclosure triggered once an investor’s stake hits the 5% threshold. While these filings sometimes hint at fresh institutional involvement, they aren’t a surefire sign of long-term buying. Australian Securities Exchange

Lynas pulls rare earths out of Mt Weld in Western Australia and handles processing both at home and in Malaysia. The company is also working on expanding into the U.S., its profile shows. These rare earths—think neodymium and praseodymium—are key ingredients for high-strength magnets inside electric vehicles and wind turbines.

Here’s the hitch: rare-earth prices move quickly, and so do profits. If costs start outpacing what the company brings in, or if production falls short versus what traders have penciled in—after the rally that’s been going since early February—expect a rough reaction.

There’s also the broader tape to watch. If CPI numbers come in hot, talk about higher-for-longer rates in Australia could flare up again. And any fresh global trade tension? That tends to send money fleeing from commodity-linked stocks in a hurry.

Lynas is set to report earnings on Feb. 26. Investors want to see hard data on volumes and pricing, plus any shift in how management discusses the ramp-up timeline.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:55 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Telstra share price closes higher ahead of ex-dividend date — what investors watch next
Previous Story

Telstra share price closes higher ahead of ex-dividend date — what investors watch next

Shell share price today: What to watch before London opens as oil jumps and buybacks roll on
Next Story

Shell share price today: What to watch before London opens as oil jumps and buybacks roll on

Go toTop